Related Experiment Video
Updated: Apr 22, 2026
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Omacetaxine mepesuccinate in chronic myeloid leukemia
Omar Al Ustwani1, Elizabeth A Griffiths, Eunice S Wang
1Roswell Park Cancer Institute, Department of Medicine, Leukemia Section , Elm and Carlton Street, Buffalo, NY 14263 , USA +001 716 845 8447 ; +001 716 845 2343 ; Meir.Wetzler@RoswellPark.org.
Introduction:
Homoharringtonine (HHT) and other alkaloid esters were originally isolated from the Cephalotaxus evergreen tree and have been used in traditional Chinese medicine since the 1970s to treat a variety of malignancies. Although HHT was investigated for the treatment of chronic myeloid leukemia (CML) in the 1990s with good results, the advent of BCR-ABL1 tyrosine kinase inhibitors (TKIs) at that time rapidly established a new standard of care for CML. Omacetaxine mepesuccinate is a semisynthetic derivative of HHT with known clinical activity in relapsed or refractory CML following TKI therapy.
Areas Covered:
In this review, we summarize the biologic effects of HHT and its derivative, omacetaxine, in CML. Additionally, we analyze the concepts learned from the early trials using these drugs. Data from clinical trials resulting in drug approval are also reviewed.
Expert Opinion:
Omacetaxine has a clear role in the CML armamentarium for patients in chronic and accelerated phase who have failed or were intolerant to two or more TKIs.
